[{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Moderator","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Padmanee Sharma<\/i><\/u><\/presenter>. UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"a8dc927a-e4b0-4e25-a84b-1de193b2e7f8","ControlNumber":"8609","DisclosureBlock":"&nbsp;<b>&nbsp;P. Sharma:<\/b>  ; Achelois Pharmaceuticals. ; Achelois Pharmaceuticals. ; Achelois Pharmaceuticals. ; Achelois Pharmaceuticals. ; Adaptive Biotechnologies Corporation. ; Adaptive Biotechnologies Corporation. ; Adaptive Biotechnologies Corporation. ; Adaptive Biotechnologies Corporation. ; Affini-T. ; Affini-T. ; Affini-T. ; Affini-T. ; Apricity. ; Apricity. ; Apricity. ; Apricity. ; AsherBio. ; AsherBio. ; AsherBio. ; AsherBio. ; BioAlta LLC. ; BioAlta LLC. ; BioAlta LLC. ; BioAlta LLC. ; BioNTech. ; BioNTech. ; BioNTech. ; BioNTech. ; C-Reveal Therapeutics. ; C-Reveal Therapeutics. ; C-Reveal Therapeutics. ; C-Reveal Therapeutics. ; Candel Therapeutics. ; Candel Therapeutics. ; Candel Therapeutics. ; Candel Therapeutics. ; Carisma. ; Carisma. ; Carisma. ; Carisma. ; Catalio Capital Management. ; Catalio Capital Management. ; Catalio Capital Management. ; Catalio Capital Management. ; Codiak Biosciences, Inc. ; Codiak Biosciences, Inc. ; Codiak Biosciences, Inc. ; Codiak Biosciences, Inc. ; Dragonfly Therapeutics, formerly called  Equipoise Therapeutics Corporation. ; Dragonfly Therapeutics, formerly called  Equipoise Therapeutics Corporation. ; Dragonfly Therapeutics, formerly called  Equipoise Therapeutics Corporation. ; Dragonfly Therapeutics, formerly called  Equipoise Therapeutics Corporation. ; Earli Inc.. ; Earli Inc.. ; Earli Inc.. ; Earli Inc.. ; Enable Medicine. ; Enable Medicine. ; Enable Medicine. ; Enable Medicine. ; Glympse Bio. ; Glympse Bio. ; Glympse Bio. ; Glympse Bio. ; Hengenix. ; Hengenix. ; Hengenix. ; Hengenix. ; Hummingbird Bioscience. ; Hummingbird Bioscience. ; Hummingbird Bioscience. ; Hummingbird Bioscience. ; ImaginAb. ; ImaginAb. ; ImaginAb. ; ImaginAb. ; Infinity Pharmaceuticals Inc.. ; Infinity Pharmaceuticals Inc.. ; Infinity Pharmaceuticals Inc.. ; Infinity Pharmaceuticals Inc.. ; InterVenn Biosciences. ; InterVenn Biosciences. ; InterVenn Biosciences. ; InterVenn Biosciences. ; JSL Health. ; JSL Health. ; JSL Health. ; JSL Health. ; LAVA Therapeutics. ; LAVA Therapeutics. ; LAVA Therapeutics. ; LAVA Therapeutics. ; Lytix Biopharma. ; Lytix Biopharma. ; Lytix Biopharma. ; Lytix Biopharma. ; Marker Therapeutics. ; Marker Therapeutics. ; Marker Therapeutics. ; Marker Therapeutics. ; Oncolytics Biotech. ; Oncolytics Biotech. ; Oncolytics Biotech. ; Oncolytics Biotech. ; PBM Capital. ; PBM Capital. ; PBM Capital. ; PBM Capital. ; Phenomic AI. ; Phenomic AI. ; Phenomic AI. ; Phenomic AI. ; Polaris Pharma. ; Polaris Pharma. ; Polaris Pharma. ; Polaris Pharma. ; Sporos. ; Sporos. ; Sporos. ; Sporos. ; Time Bioventures. ; Time Bioventures. ; Time Bioventures. ; Time Bioventures. ; Trained Therapeutix Discovery. ; Trained Therapeutix Discovery. ; Trained Therapeutix Discovery. ; Trained Therapeutix Discovery. ; Two Bear Capital. ; Two Bear Capital. ; Two Bear Capital. ; Two Bear Capital. ; Xilis, Inc. ; Xilis, Inc. ; Xilis, Inc. ; Xilis, Inc.","End":"4\/18\/2023 5:01:00 PM","HasWebcast":null,"Highlights":[],"Id":"1074","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Padmanee Sharma, MD;PhD","PresenterKey":"6ed707ff-ed42-431c-a173-4ce5a6ff2138","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Moderator","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  5:00PM","SessionId":"21","SessionOnDemand":"False","SessionTitle":"Driving Towards Rational Combination ICT Trials","ShowChatLink":"false","Start":"4\/18\/2023 5:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Moderator","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Padmanee Sharma<\/i><\/u><\/presenter>. UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"817a673f-b922-4895-8e5e-be3c1c310fd8","ControlNumber":"10293","DisclosureBlock":"<b>&nbsp;P. Sharma, <\/b> <br><b>Achelois Pharmaceuticals<\/b> I, I, I, I. <br><b>Adaptive Biotechnologies Corporation<\/b> I, I, I, I. <br><b>Affini-T<\/b> I, I, I, I. <br><b>Apricity<\/b> I, I, I, I. <br><b>AsherBio<\/b> I, I, I, I. <br><b>BioAlta LLC<\/b> I, I, I, I. <br><b>BioNTech<\/b> I, I, I, I. <br><b>C-Reveal Therapeutics<\/b> I, I, I, I. <br><b>Candel Therapeutics<\/b> I, I, I, I. <br><b>Carisma<\/b> I, I, I, I. <br><b>Catalio Capital Management<\/b> I, I, I, I. <br><b>Codiak Biosciences, Inc<\/b> I, I, I, I. <br><b>Dragonfly Therapeutics, formerly called  Equipoise Therapeutics Corporation<\/b> I, I, I, I. <br><b>Earli Inc.<\/b> I, I, I, I. <br><b>Enable Medicine<\/b> I, I, I, I. <br><b>Glympse Bio<\/b> I, I, I, I. <br><b>Hengenix<\/b> I, I, I, I. <br><b>Hummingbird Bioscience<\/b> I, I, I, I. <br><b>ImaginAb<\/b> I, I, I, I. <br><b>Infinity Pharmaceuticals Inc.<\/b> I, I, I, I. <br><b>InterVenn Biosciences<\/b> I, I, I, I. <br><b>JSL Health<\/b> I, I, I, I. <br><b>LAVA Therapeutics<\/b> I, I, I, I. <br><b>Lytix Biopharma<\/b> I, I, I, I. <br><b>Marker Therapeutics<\/b> I, I, I, I. <br><b>Oncolytics Biotech<\/b> I, I, I, I. <br><b>PBM Capital<\/b> I, I, I, I. <br><b>Phenomic AI<\/b> I, I, I, I. <br><b>Polaris Pharma<\/b> I, I, I, I. <br><b>Sporos<\/b> I, I, I, I. <br><b>Time Bioventures<\/b> I, I, I, I. <br><b>Trained Therapeutix Discovery<\/b> I, I, I, I. <br><b>Two Bear Capital<\/b> I, I, I, I. <br><b>Xilis, Inc<\/b> I, I, I, I.","End":"4\/18\/2023 5:01:00 PM","HasWebcast":null,"Highlights":[],"Id":"9069","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Padmanee Sharma, MD;PhD","PresenterKey":"6ed707ff-ed42-431c-a173-4ce5a6ff2138","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Moderator Introduction","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  5:00PM","SessionId":"21","SessionOnDemand":"False","SessionTitle":"Driving Towards Rational Combination ICT Trials","ShowChatLink":"false","Start":"4\/18\/2023 5:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Moderator Introduction","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Padmanee Sharma<\/i><\/u><\/presenter>. UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"f54c06f6-3734-466e-9b8c-33c0d1a84012","ControlNumber":"10292","DisclosureBlock":"<b>&nbsp;P. Sharma, <\/b> <br><b>Achelois Pharmaceuticals<\/b> I, I, I, I. <br><b>Adaptive Biotechnologies Corporation<\/b> I, I, I, I. <br><b>Affini-T<\/b> I, I, I, I. <br><b>Apricity<\/b> I, I, I, I. <br><b>AsherBio<\/b> I, I, I, I. <br><b>BioAlta LLC<\/b> I, I, I, I. <br><b>BioNTech<\/b> I, I, I, I. <br><b>C-Reveal Therapeutics<\/b> I, I, I, I. <br><b>Candel Therapeutics<\/b> I, I, I, I. <br><b>Carisma<\/b> I, I, I, I. <br><b>Catalio Capital Management<\/b> I, I, I, I. <br><b>Codiak Biosciences, Inc<\/b> I, I, I, I. <br><b>Dragonfly Therapeutics, formerly called  Equipoise Therapeutics Corporation<\/b> I, I, I, I. <br><b>Earli Inc.<\/b> I, I, I, I. <br><b>Enable Medicine<\/b> I, I, I, I. <br><b>Glympse Bio<\/b> I, I, I, I. <br><b>Hengenix<\/b> I, I, I, I. <br><b>Hummingbird Bioscience<\/b> I, I, I, I. <br><b>ImaginAb<\/b> I, I, I, I. <br><b>Infinity Pharmaceuticals Inc.<\/b> I, I, I, I. <br><b>InterVenn Biosciences<\/b> I, I, I, I. <br><b>JSL Health<\/b> I, I, I, I. <br><b>LAVA Therapeutics<\/b> I, I, I, I. <br><b>Lytix Biopharma<\/b> I, I, I, I. <br><b>Marker Therapeutics<\/b> I, I, I, I. <br><b>Oncolytics Biotech<\/b> I, I, I, I. <br><b>PBM Capital<\/b> I, I, I, I. <br><b>Phenomic AI<\/b> I, I, I, I. <br><b>Polaris Pharma<\/b> I, I, I, I. <br><b>Sporos<\/b> I, I, I, I. <br><b>Time Bioventures<\/b> I, I, I, I. <br><b>Trained Therapeutix Discovery<\/b> I, I, I, I. <br><b>Two Bear Capital<\/b> I, I, I, I. <br><b>Xilis, Inc<\/b> I, I, I, I.","End":"4\/18\/2023 5:21:00 PM","HasWebcast":null,"Highlights":[],"Id":"9051","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Padmanee Sharma, MD;PhD","PresenterKey":"6ed707ff-ed42-431c-a173-4ce5a6ff2138","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Investigating mechanisms of response and resistance for the development of ICT combinations","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  5:00PM","SessionId":"21","SessionOnDemand":"False","SessionTitle":"Driving Towards Rational Combination ICT Trials","ShowChatLink":"false","Start":"4\/18\/2023 5:01:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Investigating mechanisms of response and resistance for the development of ICT combinations","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Elizabeth M. Jaffee<\/i><\/u><\/presenter>. John Hopkins University, Baltimore, MD","CSlideId":"","ControlKey":"ede010d2-2af6-413f-8431-37b081fdaf62","ControlNumber":"8313","DisclosureBlock":"<b>&nbsp;E. M. Jaffee, <\/b> <br><b>Abmeta Therapeutics<\/b> O. <br><b>Achilles Therapeutics<\/b> I. <br><b>Adventris<\/b> O. <br><b>Bluedot Bio<\/b> I. <br><b>Break Through Cancer<\/b> I. <br><b>Bristol Myers Squibb Company<\/b> G. <br><b>Carta Biosciences<\/b> I. <br><b>Dragonfly Therapeutics<\/b> I. <br><b>Genentech<\/b> G. <br><b>Lustgarten Foundation<\/b> I. <br><b>Medically Home<\/b> I. <br><b>Mestag Therapeutics<\/b> I. <br><b>Orgenesis<\/b> I. <br><b>Parker Institute for Cancer Immunotherapy<\/b> I. <br><b>Patent<\/b> P.","End":"4\/18\/2023 5:41:00 PM","HasWebcast":null,"Highlights":[],"Id":"836","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Elizabeth Jaffee, MD","PresenterKey":"befc8af1-ad25-41ab-a532-b25152caee5d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"The contribution of agonists to combination immunotherapy for PD-1 resistant cancers","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  5:00PM","SessionId":"21","SessionOnDemand":"False","SessionTitle":"Driving Towards Rational Combination ICT Trials","ShowChatLink":"false","Start":"4\/18\/2023 5:21:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The contribution of agonists to combination immunotherapy for PD-1 resistant cancers","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Thomas Urban Marron<\/i><\/u><\/presenter>. The Tisch Cancer Institute, New York, NY","CSlideId":"","ControlKey":"75ab668f-ade6-44d3-8c66-9d7c0c464f34","ControlNumber":"8314","DisclosureBlock":"&nbsp;<b>T. U. Marron, <\/b> None.","End":"4\/18\/2023 6:01:00 PM","HasWebcast":null,"Highlights":[],"Id":"837","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Thomas Marron, MD;PhD","PresenterKey":"af28ac2a-1440-461a-b206-db222d7b3154","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Rationally designing combination immunotherapy trials: Identifying biomarkers prior to Phase 3","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  5:00PM","SessionId":"21","SessionOnDemand":"False","SessionTitle":"Driving Towards Rational Combination ICT Trials","ShowChatLink":"false","Start":"4\/18\/2023 5:41:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Rationally designing combination immunotherapy trials: Identifying biomarkers prior to Phase 3","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"4fffdf28-ea4f-4289-9050-ffe62b563fd6","ControlNumber":"8610","DisclosureBlock":"","End":"4\/18\/2023 6:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"1075","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Panel Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  5:00PM","SessionId":"21","SessionOnDemand":"False","SessionTitle":"Driving Towards Rational Combination ICT Trials","ShowChatLink":"false","Start":"4\/18\/2023 6:01:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Panel Discussion","Topics":null,"cSlideId":""}]